Understanding GLP-1 analogues: nature, mechanisms and specificities
Over the past fifteen years, the GLP-1 analogue class has established itself as one of the mainstays of type 2 diabetes management. These substances, almost exact copies of the human incretin GLP-1 (Glucagon-Like Peptide-1), play a direct role in regulating carbohydrate metabolism. For example, exenatide – one of the first analogues used – is derived from a protein identified in the venom of the Gila monster, a reputedly venomous reptile of the North American desert. This discovery has, it should be emphasized, opened the way to a new therapeutic range that many diabetic patients would never have imagined possible twenty years ago.
These GLP-1 agonists stimulate insulin production by pancreatic β-cells when glycemia requires it (it’s glucose dependence that ensures their safety), inhibit glucagon secretion, slow gastric emptying and enhance the sensation of satiety – mechanisms now well understood by endocrinologists, but sometimes still poorly explained during consultations. This multi-factorial mode of action promotes more regular glycemic homeostasis, protects against weight gain (the opposite effect of conventional insulin) and, in some cases, leads to significant weight reduction. Note: patients often report a marked change in their appetite, from the very first weeks.
Among the references marketed worldwide and recommended by learned societies:
Exenatide and its extended-release format (Byetta, Bydureon)
Liraglutide (Victoza, Saxenda for obesity management)
Dulaglutide (Trulicity)
Semaglutide (Ozempic, Wegovy)
Administration remains essentially by subcutaneous injection, on a weekly or daily basis depending on the formulation – pre-filled pens or sustained-release injectable solutions as appropriate. These treatments, validated by the EMA, ANSM and their international counterparts (WHO, FDA), are reserved for type 2 diabetic patients whose disease is resistant to oral antidiabetics – particularly if overweight or metabolic complications are at the forefront. In France and Europe, access to these molecules is under strict medical indications, a point often reiterated in clinical meetings and training groups.
To remember:
GLP-1 analogues actively control post-prandial and fasting blood glucose levels, thanks to adaptive insulin secretion.
Frequently in obese or severely overweight diabetic patients, they make it possible to achieve weight loss that is considered lasting and valuable in current practice.
Essential features of GLP-1 analogues:
Discovery based on biological innovation (Gila monster venom), emblematic of translational research
Joint effects on insulin secretion, glucagon inhibition, regulation of gastric emptying rate and appetite
Flagship molecules: exenatide, liraglutide, dulaglutide, semaglutide (some available in weekly form)
Administration mainly by subcutaneous injection: pre-filled pens, sustained-release solutions
Indications: inadequately balanced type 2 diabetes, often combined with metformin, with growing interest in cardiovascular prevention and multi-factorial management of metabolic pathology
Clear illustrations make it easier to understand the specific mode of action of GLP-1 agonists, especially for patients new to the field.
Clinical efficacy and indications: what recent data show
Large clinical studies and medico-administrative databases such as those of Epi-Phare, the Drugs-SafeR Bordeaux center or the SNDS network today provide a fine map of the efficacy of GLP-1 analogues in diabetic patients:
HbA1c lowering is around -1%, with rapid onset of action and lasting efficacy observed over several years (notably in studies on exenatide and liraglutide).
Weight loss, meanwhile, is generally between -2 and -6 kg depending on the molecule and adherence to treatment. In fact, it’s on this criterion that the difference with insulin glargine is most noticeable: where insulin tends to cause weight gain, GLP-1 analogues often invite the opposite slope.
For the cardiovascular component, multicenter trials (LEADER, REWIND, SUSTAIN, STEP) show a reduction of around 15% in cardiovascular mortality and major events (heart attack, stroke), mainly with liraglutide and semaglutide.
Finally, the risk of hypoglycemia – a real nightmare for many type 2 diabetic patients – remains really low, unless GLP-1 is combined with insulin or a hypoglycemic sulfonamide.
In France, the number of patients benefiting from GLP-1 analog therapy has risen from 100,000 in 2016 to over 700,000 in 2023; it is estimated that this figure could soon reach 1 million. This meteoric growth reflects both the expansion of indications (type 2 diabetes, obesity, post-surgical prevention) and the increased role of pharmaceutical groups and international recommendations in the clinical shift.
The management of obesity – whether or not associated with type 2 diabetes – is increasingly among the officially recognized indications (high-dose liraglutide, semaglutide / Wegovy), driven by the Caisse Nationale d’Assurance Maladie, health authorities and the Comité Scientifique Temporaire (CST).
A summary table situates today’s leading molecules:
| Molecule | Average HbA1c reduction | Typical weight loss | Cardiovascular benefit | Frequency of administration | Main indications |
|---|---|---|---|---|---|
| Exenatide | ≈ -1% | -2 to -4 kg | Not demonstrated | 1x/day (Byetta) or 1x/week (Bydureon) | DT2 poorly controlled, ± obesity |
| Liraglutide | ≈ -1% | -3 to -5 kg | Yes (LEADER studies) | 1x/day | DT2, obesity (Saxenda) |
| Dulaglutide | ≈ -1% | -2 to -3 kg | Yes (REWIND studies) | 1x/week | DT2 with CV risk |
| Semaglutide | -1 to -1,5% | -4 to -6 kg | Yes (SUSTAIN, STEP studies) | 1x/week | DT2, obesity (Wegovy), CV prevention |
This table puts key figures into perspective to select, in practice, the most appropriate therapeutic option according to the patient’s profile – it’s rarely a purely theoretical choice!
Our opinion
The advent of GLP-1 agonists has revolutionized the management of patients with type 2 diabetes, particularly when weight control and cardiovascular risk prevention are central concerns. Their triple ability to adjust glycemia, reduce weight and preserve the cardiovascular system has redefined the therapeutic hierarchy, where conventional insulin often found itself at the end of the road.
The boom in prescribing – including for off-label indications such as body transformation – makes this clear: it’s not uncommon for patients to explicitly ask for “the injection that makes you lose weight”. This point needs to be kept in check: going beyond the appeal of innovation requires serious support – close follow-up, clarity on therapeutic compliance, and real counseling on tolerance and side-effects are the pillars for maintaining truly effective long-term management.
Side-effects and monitoring: vigilance, safety and updated recommendations
Tolerance data on GLP-1 agonists, whether in diabetic patients or those treated for obesity, remain reassuring, even if pharmacovigilance (ANSM, EMA, WHO) calls for real vigilance – a few cases reported by the Limoges and Montpellier CRPV Centers have raised debate among clinicians.
Main adverse effects observed:
Digestive disorders:
Nausea (up to 30% of patients treated)
Vomiting, diarrhea (transient, particularly when starting or changing dose). Sometimes, according to some caregivers, tolerance varies greatly from patient to patient, sometimes even depending on the type of molecule used.
Some cases of acute pancreatitis, fortunately rare, require immediate discontinuation of treatment.
A theoretical risk – never totally ruled out – of pancreatic or thyroid cancer: no formal proof (so far, at least), but caution dictates accelerated monitoring during prolonged use. This issue regularly crops up at meetings of the Temporary Scientific Committee.
Rapid recovery of weight and blood sugar levels if treatment is discontinued. Hence, once again, the value of close monitoring and well-conducted initial therapeutic education.
Possibility, albeit rare, of local injection site reactions or allergies, identified in a few pharmacoepidemiology cohorts.
Points to watch:
Progressive dose titration: most digestive disorders subside over several days, but it’s essential to explain this course to patients right from consent.
Monitoring for any atypical abdominal pain: think pancreatitis (rare but serious).
Information on the risks of injector pen tampering, especially after EMA and WHO alerts since 2022.
Reporting and monitoring of detour for cosmetic purposes or outside the scope of AMM, especially among a young population or influenced by social networks.
Enhanced vigilance by CRPVs: Limoges, Montpellier, Paris, Bordeaux.
Don’t hesitate to ask about the warning signs and recommended steps to take in the event of an adverse reaction – dialogue remains essential, especially during follow-up at home.
Current position: consensus, recommendations and therapeutic developments
The main reference frameworks: EMA at European level, HAS and ANSM in France, WHO and ADA/EASD internationally, display reinforced consistency. GLP-1 analogues are now essential in the treatment of type 2 diabetic patients who have failed oral therapy, in cases of overweight, and above all in situations of metabolic or cardiovascular co-morbidities.
Field practice, on the other hand, insists on an individualized rationale for each patient:
GLP-1s often replace or accompany insulin eguldec or glargine in type 2 diabetic patients with obesity or high cardiovascular risk, or insulin intolerance.
Their generalized prescription for type 1 diabetes, or in a cosmetic logic, remains excluded (it’s clearly not for everyone!).
Other classes exist (DPP4, SGLT2, basal insulin), and arbitration is based on risk profile, accessibility, and above all long-term therapeutic compliance.
| Clinical situation | Place of GLP-1 analogues | Main alternatives |
|---|---|---|
| DT2 with insufficient control on orals | GLP-1 to be preferred (especially in obese or CV history) | basal insulin, SGLT2 inhibitors |
| DT2 with cardiovascular history | GLP-1 as relay after metformin | SGLT2 (shared position) |
| DT2 : weight gain on insulin/DPP4 | Addition or replacement with GLP-1 | Insulin dose reduction, hygienic-dietary measures |
| Overweight/obesity without diabetes (specific MA) | Liraglutide, semaglutide (as per MA) | Lifestyle measures |
An updated referral scheme now pragmatically informs management strategy: caregivers increasingly rely on it to discuss case-by-case with patients.
Challenges, prospects and innovations: towards the new generation of incretinomimetics
The coming decade promises to be rich in innovations in the field of type 2 diabetes and the multi-factorial management of metabolic comorbidities. Several developments are already taking shape:
New molecules in development:
GIP-GLP-1 double agonists, such as tirzepatide – the result of research conducted by major pharmaceutical groups, and already in major clinical trials in the USA and Europe. They are expected to be more effective in terms of glycemic control and weight loss.
Oral forms of semaglutide: offered in certain markets, these alternatives could facilitate therapeutic adherence in patients refractory to injection. Of note: a patient surveyed at a Cornell teaching hospital reported significantly better adherence since the change in dosage form.
New focus on therapeutic education and psychological support:
Support is no longer limited to prescribing: education, individualized adjustment of the treatment pathway, management of disorders linked to the change of treatment and psychological support around the transition have gained in importance. Experience teaches that a well-informed patient invests more, sometimes even in co-construction with his or her doctor.
Therapeutic education strategies are now integrated into international recommendations as well as into the action plans of national authorities.
Pharmacoepidemiology issues:
Numerous national programs are in place to monitor, in real time, the occurrence of serious adverse reactions and to analyze more finely the proportion of prescriptions outside official indications – notably for aesthetic weight management.
Several pharmaco-epidemiological studies are underway, piloted by Epi-Phare and the Centre Drugs-SafeR Bordeaux.
Tougher regulatory framework:
- Health authorities (ANSM, EMA) announce stricter controls, promoting proper use and limiting misuse for bodily purposes or counterfeit injection pens.
Evolution of the pathway and referral criteria:
- The evolution of therapeutic referral criteria (HAS, learned societies) is supported by ongoing training for caregivers; the care pathway is now intended to be co-constructed, taking into account the entire metabolic situation and daily reality of diabetic patients, a far cry from the standardized model of ten years ago.
Future developments point to a revolution in the personalization of management strategies for type 2 diabetes and its complications: a new page is being turned, one that patients and clinicians are beginning to write together.
